PV Bulletin

Swissmedic Guidance on Injectable Products for Wrinkle Treatment

Updated guidance clarifying the classification and professional use requirements for injectable aesthetic products, such as botulinum toxin and dermal fillers.

Primary source: Swissmedic

PV Impact Brief

Urgency: HighConfidence: high

What changed

Botulinum toxin is now confirmed as prescription-only, and strict safety and professional use requirements for dermal fillers are mandated under the MedDO.

Why it matters

These changes necessitate healthcare professionals to adhere to new reporting and compliance measures concerning injectable products, ultimately aiming to enhance patient safety.

Action needed

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance
Policy status
final
Publication date
June 19, 2026
Policy change
Updated guidance clarifying the regulatory classification and professional use requirements for injectable aesthetic products, such as botulinum toxin and dermal fillers.

Key changes

Confirms botulinum toxin as prescription-only; mandates strict safety and professional use requirements for dermal fillers under MedDO.

Affected workflows

Country Compliance

Responsible groups

MAHsMedical Affairs

PV impact

Reinforces risk management and safety monitoring for aesthetic medicinal products and devices.

View regulator source

Source document details

Exact policy details

Version
4.0
Applies to: Applicable to the information sheet on injectable products for wrinkle treatment.
Document version stated on page 1. · p. 1 · High · Source
Valid from
19.06.2026
Applies to: Date from which the version of the document is effective.
Effective date noted on page 1. · p. 1 · High · Source
Authorization Requirement for Injectable Products
Botulinum toxin must be authorized as medicinal products.
Applies to: Applies to all injectable products classified as medicinal products.
Stated on page 3 regarding botulinum toxin preparations. · p. 3 · High · Source
Conformity Assessment Requirement
Products containing hyaluronic acid, along with others, must undergo a conformity assessment procedure.
Applies to: Applicable to injectable products regulated by the Medical Devices Ordinance.
Highlighted on page 4 and page 6. · p. 4 · High · Source
Reporting Obligation
Healthcare professionals must report all serious incidents involving the use of such devices to Swissmedic.
Applies to: Mandatory for users of injectable devices.
Noted on page 5 under Art. 66 para. 4 MedDO. · p. 5 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 19, 2026

Full briefing

Practical implication

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

The updated information sheet from Swissmedic specifies that botulinum toxin is classified as a prescription-only medicinal product, while dermal fillers are subject to safety and professional use requirements as per the Medical Devices Ordinance (MedDO). It emphasizes mandatory risk management and safety monitoring for these aesthetic products.

What changed: Botulinum toxin is now confirmed as prescription-only, and strict safety and professional use requirements for dermal fillers are mandated under the MedDO.

Why it matters: These changes necessitate healthcare professionals to adhere to new reporting and compliance measures concerning injectable products, ultimately aiming to enhance patient safety.

Practical implication: Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#guidance#final#Swissmedic#policy-change#firecrawl-policy-agent

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward